[go: up one dir, main page]

MX2023008761A - Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo. - Google Patents

Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.

Info

Publication number
MX2023008761A
MX2023008761A MX2023008761A MX2023008761A MX2023008761A MX 2023008761 A MX2023008761 A MX 2023008761A MX 2023008761 A MX2023008761 A MX 2023008761A MX 2023008761 A MX2023008761 A MX 2023008761A MX 2023008761 A MX2023008761 A MX 2023008761A
Authority
MX
Mexico
Prior art keywords
phosphodiesterase
inhibitory activity
activity against
benzotriazole derivative
ectonucleotide pyrophosphatase
Prior art date
Application number
MX2023008761A
Other languages
English (en)
Inventor
Jung Hwan Choi
Chan Sun Park
Sun Young Park
Sung Joon Kim
Ali Imran
Sun Woo Lee
Yong Yea Park
Ah Ran Yu
Yoo Jin Na
So Ra Paik
Original Assignee
Txinno Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220012603A external-priority patent/KR102686866B1/ko
Application filed by Txinno Bioscience Inc filed Critical Txinno Bioscience Inc
Publication of MX2023008761A publication Critical patent/MX2023008761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C07F9/65188—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con un compuesto novedoso derivado de benzotriazol, un tautómero del mismo, una sal farmacéuticamente aceptable del mismo, un hidrato del mismo, o un estereoisómero del mismo, los cuales se relacionan con un compuesto para inhibir la ENPP1, una composición para inhibir la ENPP1, y un método para inhibir la ENPP1.
MX2023008761A 2021-01-29 2022-01-28 Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo. MX2023008761A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210013052 2021-01-29
KR1020220012603A KR102686866B1 (ko) 2021-01-29 2022-01-27 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
PCT/KR2022/001548 WO2022164249A1 (ko) 2021-01-29 2022-01-28 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도

Publications (1)

Publication Number Publication Date
MX2023008761A true MX2023008761A (es) 2023-08-22

Family

ID=82653640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008761A MX2023008761A (es) 2021-01-29 2022-01-28 Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.

Country Status (8)

Country Link
US (1) US20240116882A1 (es)
EP (1) EP4286374A4 (es)
JP (1) JP2024505216A (es)
KR (1) KR20240113429A (es)
AU (1) AU2022211957B2 (es)
CA (1) CA3204409A1 (es)
MX (1) MX2023008761A (es)
WO (1) WO2022164249A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118908989B (zh) * 2024-10-10 2024-12-17 江苏长泰药业股份有限公司 一种用于预防肺结节恶性转化的丙酮酸盐衍生物纳米雾化剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085782A1 (en) 2016-12-22 2020-03-19 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
CA3047589A1 (en) 2016-12-22 2018-06-28 Mavupharma, Inc. Phosphodiesterase inhibitors and methods of microbial treatment
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
WO2019046778A1 (en) * 2017-08-31 2019-03-07 Mavupharma, Inc. INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP-1) AND USES THEREOF
HUE066413T2 (hu) 2017-09-08 2024-08-28 Univ Leland Stanford Junior ENPP1 inhibitorok és alkalmazásuk rák kezelésére
WO2019177971A1 (en) 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
CN110575458A (zh) 2018-06-09 2019-12-17 杭州星鳌生物科技有限公司 一种抗肿瘤复方药物的组成及其在抗肿瘤中的应用
JP2020015670A (ja) 2018-07-23 2020-01-30 公立大学法人名古屋市立大学 Ｅｎｐｐ１阻害剤及びその用途
EP3829561A4 (en) 2018-08-01 2021-12-29 Stingray Therapeutics, Inc. Substituted-3h-imidazo[4,5-c]pyridine and 1h pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics
JP7598875B2 (ja) * 2019-04-12 2024-12-12 リボサイエンス リミティド ライアビリティ カンパニー エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体

Also Published As

Publication number Publication date
WO2022164249A1 (ko) 2022-08-04
EP4286374A1 (en) 2023-12-06
KR20240113429A (ko) 2024-07-22
CA3204409A1 (en) 2022-08-04
AU2022211957B2 (en) 2024-05-23
US20240116882A1 (en) 2024-04-11
AU2022211957A1 (en) 2023-07-27
JP2024505216A (ja) 2024-02-05
EP4286374A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2020006315A (es) Acidos carbamoil ciclohexilicos ligados a n triazol como antagonistas de acido lisofosfatidico (lpa).
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
MX2020005818A (es) Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
MY162936A (en) Macrocycles as factor xia inhibitors
MX373102B (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
EA202193015A1 (ru) Ингибиторы cdk
ZA202307945B (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
ZA202202245B (en) Quinoline derivatives as protein kinase inhibitors
MX2021000051A (es) Inhibidores de triazol glicolato oxidasa.
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12019550154B1 (en) Azetidine derivative
MX2023008761A (es) Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MY156955A (en) Antifungal agents
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2021026479A9 (en) Small molecule inhibitors of s1p2 receptor and uses thereof
MX2023007670A (es) Nuevo derivado de naftiridinona que tiene actividad inhibidora contra la ectonucleotido pirofosfatasa -fosfodiesterasa y uso del mismo.
PH12021550248A1 (en) Borate of azetidine derivative